文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

沙库巴曲缬沙坦用于需要血液透析的患者

Sacubitril-Valsartan in Patients Requiring Hemodialysis.
PubMed 文献 · JAMA Netw Open · 2024-08-01
一句话结论在需要血液透析的HFrEF患者中,沙库巴曲缬沙坦与ACEI或ARB相比与全因死亡和全因住院减少相关,心血管死亡和心衰住院无差异。

这项回顾性、1:1倾向评分匹配的比較效益研究纳入2015年7月8日至2020年12月31日期间接受中心血液透析至少90天的18岁以上HFrEF Medicare患者,比较新启用沙库巴曲缬沙坦与新用或续用ACEI或ARB的结局。匹配后沙库巴曲缬沙坦组与ACEI或ARB组各1434例,中位随访0.9年。沙库巴曲缬沙坦与全因死亡(HR 0.82,95%CI 0.73-0.92)和全因住院(HR 0.86,95%CI 0.79-0.93)减少相关,心血管死亡(HR 1.01,95%CI 0.86-1.19)和心衰住院(HR 0.91,95%CI 0.82-1.02)无差异。高钾血症减少(HR 0.71,95%CI 0.62-0.81),低血压无差异(HR 0.99,95%CI 0.83-1.19)。仅195例(14%)曾接受沙库巴曲97 mg每日两次和缬沙坦103 mg每日两次的最大联合剂量。

要点

  • 在需要血液透析的HFrEF患者中,沙库巴曲缬沙坦与ACEI或ARB相比,全因死亡风险降低(HR 0.82,95%CI 0.73-0.92)。
  • 沙库巴曲缬沙坦组全因住院风险也较低(HR 0.86,95%CI 0.79-0.93),但心血管死亡(HR 1.01,95%CI 0.86-1.19)和心衰住院(HR 0.91,95%CI 0.82-1.02)与ACEI或ARB组无差异。
  • 沙库巴曲缬沙坦组高钾血症减少(HR 0.71,95%CI 0.62-0.81),低血压无差异(HR 0.99,95%CI 0.83-1.19)。
  • 仅195例(14%)曾接受沙库巴曲97 mg每日两次和缬沙坦103 mg每日两次的最大联合剂量。
  • 该研究为回顾性、1:1倾向评分匹配的比較效益研究,中位随访0.9年。

适用人群与场景

  • 18岁及以上、HFrEF、参加Medicare Parts A、B和D、接受中心血液透析至少90天且存活的患者,纳入时间为2015年7月8日至2020年12月31日。
  • 排除连续Medicare Parts A、B和D主支付方覆盖少于180天或既往配发过沙库巴曲缬沙坦的患者。

研究设计与关键结果

  • 研究类型:回顾性、1:1倾向评分匹配的比較效益研究。
  • 样本量:匹配后沙库巴曲缬沙坦组1434例与ACEI或ARB组1434例,共2868例;平均(SD)年龄64(13)岁;996例(65%)为男性;987例(34%)为黑人或非裔美国人,1677例(58%)为白人;中位透析龄3.8(IQR 1.8-6.3)年。
  • 干预与对照:新启用沙库巴曲缬沙坦 vs 新用或续用ACEI或ARB。
  • 主要终点:沙库巴曲缬沙坦与全因死亡减少相关(HR 0.82,95%CI 0.73-0.92)和全因住院减少相关(HR 0.86,95%CI 0.79-0.93);心血管死亡无差异(HR 1.01,95%CI 0.86-1.19);心衰住院无差异(HR 0.91,95%CI 0.82-1.02)。
  • 不良事件:高钾血症减少(HR 0.71,95%CI 0.62-0.81);低血压无差异(HR 0.99,95%CI 0.83-1.19)。
  • 中位随访0.9(IQR 0.4-1.7)年;仅195例(14%)曾接受沙库巴曲97 mg每日两次和缬沙坦103 mg每日两次的最大联合剂量。

证据类型、等级与局限

  • 证据类型:回顾性、1:1倾向评分匹配的比較效益研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在需要血液透析的HFrEF患者中,沙库巴曲缬沙坦治疗与全因死亡和全因住院的获益相关。
  • 沙库巴曲缬沙坦与ACEI或ARB相比,心血管死亡和心衰住院无差异。
  • 沙库巴曲缬沙坦组高钾血症减少,低血压无差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Randomized clinical trials have shown that sacubitril-valsartan reduces the risks of mortality and hospitalization in patients with heart failure with reduced ejection fraction (HFrEF), but patients with kidney failure requiring dialysis were excluded.

OBJECTIVE: To investigate the comparative effectiveness of sacubitril-valsartan vs angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEIs or ARBs) in patients with HFrEF requiring hemodialysis.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective, 1:1 propensity score-matched comparative effectiveness study included patients who were 18 years or older with HFrEF, enrolled in Medicare Parts A, B, and D, and survived at least 90 days receiving in-center hemodialysis from July 8, 2015, to December 31, 2020. Patients were excluded for less than 180 days of continuous Medicare Parts A, B, and D primary payer coverage or prior dispensing of sacubitril-valsartan. Data analysis was conducted from September 23, 2023, to June 25, 2024.

EXPOSURES: New use of sacubitril-valsartan vs new or continued use of ACEIs or ARBs.

MAIN OUTCOMES AND MEASURES: The associations between initiation of sacubitril-valsartan therapy and all-cause mortality, cardiovascular mortality, all-cause hospitalization, and HF hospitalization were assessed using Cox proportional hazards regression models in a propensity score-matched sample.

RESULTS: Participants included 1:1 matched pairs of 1434 sacubitril-valsartan users and 1434 ACEI or ARB users (mean [SD] age, 64 [13] years). Of the 2868 matched participants, 996 (65%) were male; 987 (34%) were Black or African American and 1677 (58%) were White; and median dialysis vintage was 3.8 (IQR, 1.8-6.3) years. The median follow-up was 0.9 (IQR, 0.4-1.7) years. Sacubitril-valsartan (vs ACEI or ARB) therapy was associated with a reduction in all-cause mortality (hazard ratio [HR], 0.82 [95% CI, 0.73-0.92]) and all-cause hospitalization (HR, 0.86 [95% CI, 0.79-0.93]) but not cardiovascular mortality (HR, 1.01 [95% CI, 0.86-1.19]) or HF hospitalization (HR, 0.91 [95% CI, 0.82-1.02]). There was a decrease in hyperkalemia (HR, 0.71 [95% CI, 0.62-0.81]) and no difference in hypotension (HR, 0.99 [95% CI, 0.83-1.19]). Only 195 participants (14%) ever received the maximum combination dose of sacubitril (97 mg twice daily) and valsartan (103 mg twice daily).

CONCLUSIONS AND RELEVANCE: In this comparative effectiveness study of patients with HFrEF requiring hemodialysis, sacubitril-valsartan therapy was associated with beneficial effects in all-cause mortality and all-cause hospitalization.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Le D, Grams ME, Coresh J, et al. Sacubitril-Valsartan in Patients Requiring Hemodialysis. JAMA Netw Open. 2024. PMID: 39163041. doi:10.1001/jamanetworkopen.2024.29237

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。